Gedeon Richter Spends Most On Biosimilar R&D

Multiple Candidates In Clinical Phase Including Denosumab

Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.

Clinical_Trial_Globe
Biosimilar Prolia/Xgeva and Actemra/RoActemra candidates are entering the clinical phase • Source: Shutterstock

Gedeon Richter’s research and development spending was topped by biosimilar investment in the first nine months of this year, as the Hungarian firm continues to advance multiple candidates and support a growing portfolio of products.

Group R&D expenses were 17.1% higher at HUF42.8bn ($141m), according to figures just released by the company. Of that amount,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.